Management of Diffuse Alveolar Hemorrhage

Diagnosis and Initial Assessment

The diagnosis of DAH is established through bronchoalveolar lavage (BAL) showing increasingly bloody returns in sequential aliquots, according to the American Journal of Respiratory and Critical Care Medicine 1
DAH with hypoxemia has a high early mortality risk and requires prompt intervention, as stated by Kidney International 2, 3

Etiology Assessment

In ANCA-associated vasculitis (AAV), DAH occurs in approximately 25% of patients, according to the American Journal of Kidney Diseases 4
Risk factors for mortality in AAV-associated DAH include older age, severe kidney failure, degree of hypoxemia, and involvement of >50% of lung area, as reported by the American Journal of Kidney Diseases 4, 5

Treatment Algorithm

The American Society of Apheresis recommends plasma exchange for severe DAH, as stated by the American Journal of Kidney Diseases 4
High-dose glucocorticoids (intravenous) plus either cyclophosphamide or rituximab is the standard of care for patients with DAH and hypoxemia, according to the American Journal of Kidney Diseases and Kidney International 4, 2, 3
Plasma exchange should be considered for DAH with hypoxemia, despite the PEXIVAS trial not showing clear benefit in the primary composite outcome, as reported by the American Journal of Kidney Diseases and Kidney International 4, 2, 5

Special Considerations

DAH without hypoxemia generally has a more benign prognosis and responds as the underlying disease is controlled, according to Kidney International 2, 3
In patients with DAH and renal involvement (pulmonary-renal syndrome), aggressive immunosuppression is critical, as stated by the American Journal of Kidney Diseases 4
Patients with refractory disease should be referred to centers with expertise in vasculitis, as recommended by the American Journal of Kidney Diseases 4, 5

Monitoring and Follow-up

Monitor for treatment response with clinical symptoms, oxygenation parameters, and radiographic improvement, as suggested by the Journal of the American College of Radiology 6
For patients with AAV, continue maintenance immunosuppression after remission to prevent relapse, according to Kidney International 2, 7
For kidney transplant candidates with history of AAV and DAH, delay transplantation until complete clinical remission for ≥6 months, as recommended by the American Journal of Kidney Diseases and Kidney International 4, 2

Prognosis

Mortality risk is more closely associated with the rate of hemoptysis rather than the quantity, as reported by the Journal of the American College of Radiology 6

Management of Diffuse Alveolar Hemorrhage

Specific Immunosuppressive Therapy

The Kidney International guideline recommends considering avacopan as an adjunctive therapy to reduce glucocorticoid exposure, particularly in patients at high risk for steroid toxicity, in DAH associated with ANCA-associated vasculitis (AAV) or other autoimmune causes 8

Plasma Exchange Considerations

The Kidney International guideline suggests plasma exchange for patients with DAH who have specific indications, including serum creatinine >3.4 mg/dl, requiring dialysis, or with rapidly increasing serum creatinine, diffuse alveolar hemorrhage with hypoxemia, or concomitant anti-glomerular basement membrane (GBM) disease 8

Prognosis and Complications

The Anaesthesia guideline recommends standard venous thromboprophylaxis should be commenced as soon as possible after bleeding has been controlled, as patients rapidly develop a prothrombotic state 9

Etiology-Specific Management

The Kidney International guideline recommends continuing maintenance immunosuppression after remission for 18 months to 4 years to prevent relapse in patients with AAV 8

Management of Alveolar Hemorrhage

Contraindications and Risks

The European Respiratory Society guidelines warn that manual hyperinflation can precipitate marked hemodynamic changes and decreased cardiac output from large fluctuations in intrathoracic pressure, particularly dangerous when alveolar capillaries are already disrupted and bleeding 10
Manual hyperinflation creates pressure fluctuations that can extend capillary damage and worsen hemorrhage 10
Postural drainage with head-down positioning may increase pulmonary blood flow to damaged areas and exacerbate bleeding 10
Percussion and vibratory shaking can cause direct mechanical trauma to hemorrhaging lung tissue 10
Forced expiration techniques and assisted cough generate high intrathoracic pressures that can propagate bleeding 10, 11

Treatment Algorithm

The American College of Rheumatology recommends initiating high-dose intravenous glucocorticoids plus either cyclophosphamide or rituximab immediately if immune-mediated DAH is suspected (ANCA-associated vasculitis, Goodpasture syndrome, connective tissue disease) 12
Consider plasma exchange for DAH with hypoxemia, particularly if serum creatinine is elevated, requiring dialysis, or concomitant anti-GBM disease, despite mixed evidence from PEXIVAS trial 12

Ventilator Management

Use lung-protective ventilation strategies with tidal volumes of 6-8 mL/kg predicted body weight 13
Maintain plateau pressure ≤30 cmH₂O 13
Use moderate levels of PEEP (6-8 cmH₂O) to maintain oxygenation while avoiding high recruitment pressures that could worsen bleeding 13
Avoid aggressive recruitment maneuvers, as continuous positive airway pressure recruitment at 35 cmH₂O has been shown to increase ICP and decrease cerebral perfusion pressure in similar populations 13

Critical Monitoring Parameters

Track oxygenation parameters, such as PaO₂/FiO₂ ratio improvement, to determine when bleeding is controlled 13
Monitor chest imaging for resolution of ground-glass opacities and consolidation 14

Steroid Dosing for Diffuse Alveolar Hemorrhage in Microscopic Polyangiitis

Initial Pulse Steroid Therapy

For patients with Microscopic Polyangiitis (MPA) and diffuse alveolar hemorrhage (DAH), the American College of Rheumatology recommends initiating intravenous methylprednisolone at a cumulative dose of 1-3 grams over days 1-3, followed by high-dose oral prednisone starting at 50-75 mg/day based on body weight, with rapid taper according to a structured protocol 15, 16
Administer IV methylprednisolone 500-1000 mg/day for 3 consecutive days for patients with severely active disease including DAH, with a maximum cumulative dose of 3 grams 15, 16, 17
The 2021 ACR/Vasculitis Foundation guidelines note that the reduced-dose regimen in the PEXIVAS trial started with pulse methylprednisolone (3 daily pulses for maximum total dose of 3 gm) 17, 18

Transition to Oral Glucocorticoids

After pulse therapy, transition to high-dose oral prednisone with weight-based dosing, with the following dosages:
Continue tapering to reach 5 mg/day by weeks 19-52 15, 16

Critical Context for DAH Management

Combine glucocorticoids with either rituximab (preferred) or cyclophosphamide for remission induction 17, 18, 19
The 2021 ACR guidelines conditionally recommend against routine plasma exchange for alveolar hemorrhage based on lack of mortality benefit, but acknowledge it may be considered for critically ill patients not responding to standard therapy 18

Important Caveats

The reduced-dose glucocorticoid regimen from PEXIVAS resulted in 40% less cumulative steroid exposure while maintaining similar efficacy for the composite outcome of ESRD or death, with decreased infection risk 15, 16, 17
High-dose glucocorticoids contribute significantly to infection risk, which is the leading cause of death (48%) within the first year in MPA patients 15, 16
Do not use lower starting doses (<0.5 mg/kg/day) in patients with life-threatening manifestations like DAH 15, 16
IV pulse glucocorticoids are generally reserved for organ- or life-threatening disease but carry increased infection risk 17, 18

Prognosis and Treatment of Diffuse Alveolar Hemorrhage

Etiology-Specific Prognosis and Treatment

The American Journal of Kidney Diseases recommends aggressive early immunosuppression with cyclophosphamide, glucocorticoids, and plasmapheresis for anti-GBM disease with DAH, which improves outcomes substantially 20
Delayed treatment in anti-GBM disease results in 96% mortality, emphasizing the importance of empiric therapy when suspected, according to the American Journal of Kidney Diseases 20
Patients presenting on dialysis with anti-GBM disease have 35% mortality and >90% remain dialysis-dependent at 1 year, though those with acute presentation and favorable biopsy features may still benefit from treatment, as reported by the American Journal of Kidney Diseases 20
Delaying bronchoscopy to confirm diagnosis can worsen outcomes, particularly in immune-mediated disease where empiric treatment should begin immediately, according to the American Journal of Kidney Diseases 20